Navigation Links
Restriction Endonucleases Undergo Rigorous QC Testing to Ensure Optimal,,,Performance


Reliable restriction enzymes satisfy all your research needs

Ronda Allen Kim Kuplent
Stratagene

Restriction endonucleases are used in many molecular biology protocols, making the functional purity of critical importance. Each restriction enzyme preparation must be free of contaminants that can potentially interfere with either DNA cleavage or subsequent reactions that use digested DNA (i.e., ligation or sequencing reactions). Such contaminants might include other site-specific endonucleases that produce unwanted DNA fragments, exonucleases that destroy the integrity of the cut site by cleaving nucleotides from the resultant 5 or 3 termini of the fragments, and phosphatases that inhibit ligation reactions by removing the 5 phosphate from DNA ends. To ensure that Stratagenes enzymes consistently meet the needs of the research community, we impose strict quality control procedures in analyzing every enzyme preparation. In most instances, the testing conditions are designed to be more rigorous than typical laboratory applications. In this article, we describe the assays used to establish the functional purity of restriction endonuclease preparations.

Unit Activity Determination

Prior to assaying samples for contaminants, the unit activity of each enzyme sample is accurately determined. One unit of activity is defined as the amount of enzyme required to completely digest 1 g of substrate DNA in 1 hour at the appropriate temperature under the optimal assay conditions. This information is provided on the Certificate of Analysis provided with each restriction endonuclease. Restriction enzyme activity is substrate-dependent; therefore, when digesting a new substrate, we recommend titrating the amount of enzyme added. The unit activity of a repr
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Efficiently Insert Unique Restriction Sites into Plasmid Vectors
2. Restriction Digests of DNA Isolated with the Perfectprep Gel Cleanup Kit
3. Reliable Assessment of Micronuclei for Genotoxicity Testing in Mice or Rats
4. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
5. Sciclone ALH Bulk Dispense Precision Testing
6. 96 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array
7. Sciclone ALH 3000 Liquid Handler: Functional Characterization of the High Volume Head - Part 1: Plate-to-Plate Precision Testing
8. Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option
9. 384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler
10. Testing Compressed Air Lines for Microbiological Contamination
11. Testing Compressed Air Lines for Microbiological Contamination

Post Your Comments:
(Date:11/6/2009)...ewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:...today announced updated results from a Phase II st...rcomas metastatic to the lung in a poster presenta... Society Meeting held in Miami Beach, Florida, fro...titled "A Phase II Study of Intravenous REOLYSIN (...
(Date:11/5/2009)...e hybrid . . . , Fuel economy ratings for the ...the www.fueleconomy.gov web site, which Oak Ridg...the U.S. Department of Energy and the U.S. Environ...les on the best fuel economy list are hybrid elect...hway). "This list proves that hybrids have gone ma...
(Date:11/5/2009)...v. 5 DSM Pharmaceutical Products t...liance with Galenix, Saint Jean D,Illac, France, w...nufacturing partner for Galenix commercial product...llaborate on business development opportunities co...ed on the strength of Galenix in drug product deve...
(Date:11/5/2009)...hursday, November 5, 2009 at 4:30 p.m. Eastern Tim...ire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (...ay reported unaudited financial results for the th...09 and reviewed the Company,s highlights for the t...ated results reflect the operations of OncoGenex T...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...Sales Reach $11.7 Million, PRINCETON, N.J., May 1..., a provider of advanced wound-care products,annou...ch 31, 2008. For the,quarter, sales were up 47 per...the newly acquired First Aid Division. The Company... due primarily to higher than expected,integration...
...Highlights: - IND for liquid formulation, NGX-19...inical development expected in second quarter of 2...n PHN expected in second half ...view for peripheral neuropathic pain, SAN MATEO, ...a biopharmaceutical company focused on developing ...
...Company secures global supply of top-quality custo...nd marketing executive, NEWBURGH, NY, USA and LIV...nics, developer of the i-LIMB Hand, the world,s fi...nic hand, today announced that it has,acquired the...of the unique,and lifelike prosthetic skin that To...
Other Biology Technology:Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5NeurogesX Reports First Quarter 2008 Results 2NeurogesX Reports First Quarter 2008 Results 3NeurogesX Reports First Quarter 2008 Results 4NeurogesX Reports First Quarter 2008 Results 5NeurogesX Reports First Quarter 2008 Results 6NeurogesX Reports First Quarter 2008 Results 7Touch Bionics acquires LIVINGSKIN 2Touch Bionics acquires LIVINGSKIN 3
(Date:11/5/2009)...n.Researchers at Yale University have developed sy...immune response to HIV and HIV-infected cells, as ...published online in the Journal of the American C...approaches for these diseases. , The molecules ...V" (ARM-H) and "antibody-recruiting molecule targe...
(Date:11/4/2009)...Although scientists are reluctant to officially en...dence continues to grow about its protective effec... Cancer Prevention Research , a journal of the Ame...sts some reduction in oral cancer. , Vassiliki ... the Department of Thoracic/Head and Neck Medical ...
(Date:11/4/2009)...corridors in the cities of Long Beach and Riversid...preventable childhood asthma, and the true impact ... has likely been underestimated, according to rese...USC). , The study, which appears in an online e... estimated that nine percent of all childhood asth...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Beginning Swim Classes Too Advanced for Many Beginners 3B Swim Instructor Conference Slated 50151 1Beginning Swim Classes Too Advanced for Many Beginners 3B Swim Instructor Conference Slated 50151 2Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 1Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 2Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 3Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 4Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 5JustGetTested com Offers Fast Confidential HIV Testing to Mark National HIV Testing Day 50147 1JustGetTested com Offers Fast Confidential HIV Testing to Mark National HIV Testing Day 50147 2
...chers at Yale School of Medicine have found eviden... stimulates the higher brain functions of spatial ...sts that we may learn best on an empty stomach. , ...e Neuroscience by investigators at Yale and other ...lin, produced in the stomach and previously associ...
...ists have found that growth hormone, a substance t...ain, according to an article published in this wee...s. , The researchers -- from three institutions –?...ippocampus, a structure deep inside the brain that...ists also found that more growth hormone is produc...
...eriments with mice, researchers have found that el...ch for the development of pain-sensing neurons kno...." Such pain is abnormal pain that outlasts the in...ervous system changes. The animals rendered defici... response to discomfort caused by heat and cold an...
Other Biology News:Learning and memory stimulated by gut hormone 2Growth hormone is made in the brain, report scientists 2Master genetic switch found for chronic pain 2
Mouse Anti-Human SNAPC5 Monoclonal Antibody, Unconjugated, Clone 6G10 from Abnova Corporation
...Mouse monoclonal antibody raised against a partial...28, 56 a.a. ~ 145 a.a) partial recombinant protein...QHEPFLDFLLGFSAGTEYMDLQNDLGQTALHLAAILGETSTVEKLYAAGA...8 Protein Accession Number: AAH15528 OMIM: ...
...The BD PhosFlow Perm/Wash Buffer I can be used in ...ified signaling proteins to permeabilize cells and...fer. Because saponin-mediated cell permeabilizatio... the cells in the presence of saponin during intra...
Mouse Anti-Human ACTN4 Monoclonal Antibody, Unconjugated, Clone 4D10 from Abnova Corporation
Biology Products: